Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies

Liver International

Volumn 29, Issue 4, 2009, Pages 502-510

  Tandon, Puneeta ^a,b,c   Garcia Tsao, Guadalupe ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hepatocellular carcinoma; Multivariable analysis; Prognosis

Indexed keywords

ALPHA FETOPROTEIN;

CANCER CLASSIFICATION; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PORTAL VEIN THROMBOSIS; PROGNOSIS; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 62749123476     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01957.x     Document Type: Review

References (89)

1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
3. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-2.
4. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-5.
5. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
6. Diamond GA. Future imperfect: The limitations of clinical prediction models and the limits of clinical prediction. J Am Coll Cardiol 1989; 14 (Suppl. A): 12A-22A.
7. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997; 277: 488-94.
8. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-24.
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
10. Calvet X, Bruix J, Gines P, et al. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology 1990; 12 (Part 1): 753-60.
11. Akashi Y, Koreeda C, Enomoto S, et al. Prognosis of unresectable hepatocellular carcinoma: An evaluation based on multivariate analysis of 90 cases. Hepatology 1991; 14: 262-8.
12. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132-7.
13. Nomura F, Ohnishi K, Honda M, et al. Clinical features of hepatocellular carcinoma in the elderly: A study of 91 patients older than 70 years. Br J Cancer 1994; 70: 690-3.
14. Pirisi M, Fabris C, Soardo G, et al. Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma. Eur J Cancer 1996; 32A: 221-5.
15. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111: 996-1001.
16. Kouroumalis EA, Skordilis PG, Moschandrea J, et al. Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus. Eur J Gastroenterol Hepatol 1997; 9: 981-8.
17. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol 1997; 27: 661-8.
18. Tanizaki H, Ryu M, Kinoshita T, et al. Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn J Clin Oncol 1997; 27: 67-70.
19. Ebara M, Hatano R, Fukuda H, et al. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 1998; 45(Suppl. 3): 1214-20.
20. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. Am J Clin Oncol 1998; 21: 386-91.
21. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-41.
22. Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3028-33.
23. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
24. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-5.
25. Dohmen K, Shirahama M, Onohara S, et al. Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: an analysis of 547 patients. Hepatol Res 2000; 18: 110-21.
26. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 2266-73.
27. Giannini E, Arzani L, Borro P, et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology 2000; 47: 1395-8.
28. Tangkijvanich P, Janchai A, Charuruks N, et al. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pac J Allergy Immunol 2000; 18: 237-43.
29. Farinati F, Gianni S, Marin G, et al. Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis? Eur J Gastroenterol Hepatol 2001; 13: 1217-24.
30. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: Impact of stage of disease. Eur J Cancer 2001; 37: 239-45.
31. Schoniger-Hekele M, Muller C, Kutilek M, et al. Hepatocellular carcinoma in Central Europe: Prognostic features and survival. Gut 2001; 48: 103-9.
32. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877-80.
33. Toyoda H, Kumada T, Nakano S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 2001; 91: 957-63.
34. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529-34.
35. Giannelli G, Pierri F, Trerotoli P, et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res 2002; 24: 50.
36. Giannini E, Romagnoli P, Fasoli A, et al. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing 2002; 31: 457-62.
37. Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 2663-8.
38. Ueno S, Tanabe G, Nuruki K, et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepato Pancreat Surg 2002; 9: 469-77.
39. Kawakita T, Shiraki K, Yamanaka Y, et al. A new prognostic scoring system involving des-gamma-carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma. Int J Oncol 2003; 23: 1115-20.
40. Nagaoka S, Yatsuhashi H, Hamada H, et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98: 2671-7.
41. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. J Clin Oncol 2003; 21: 2294-8.
42. Yano Y, Yamashita F, Sumie S, et al. Clinical significance of antibody against hepatitis B virus core antigen in patients with hepatitis C virus-related hepatocellular carcinoma. Liver Int 2003; 23: 227-31.
43. Akamatsu M, Yoshida H, Shiina S, et al. Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 16: 459-66.
44. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-6.
45. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: Which is the best tool available? J Hepatol 2004; 40: 124-31.
46. Dohmen K, Shirahama M, Shigematsu H, Irie K, Ishibashi H. Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 859-65.
47. Giannini E, Risso D, Botta F, et al. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: A single-centre comparison amongst four different staging systems. J Intern Med 2004; 255: 399-408.
48. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
49. Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol 2004; 99: 2158-65.
50. Okumoto K, Hattori E, Tamura K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004; 24: 21-8.
51. Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 805-11.
52. Sakar B, Ustuner Z, Karagol H, et al. Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 2004; 27: 489-93.
53. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
54. Siddique I, El-Naga HA, Memon A, et al. CLIP score as a prognostic indicator for hepatocellular carcinoma: Experience with patients in the Middle East. Eur J Gastroenterol Hepatol 2004; 16: 675-80.
55. Tangkijvanich P, Mahachai V, Suwangool P, Poovorawan Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1547-50.
56. Toyoda H, Kumada T, Kiriyama S, et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 2004; 100: 2415-21.
57. Vejchapipat P, Tangkijvanich P, Theamboonlers A, et al. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004; 39: 1182-8.
58. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862-8.
59. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: Comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-8.
60. Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005; 20: 873-81.
61. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16.
62. Toyoda H, Kumada T, Kiriyama S, et al. Impact of tumor factors on the prognosis of patients with advanced cirrhosis (Child-Pugh class C) and hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 963-5.
63. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005; 100: 1764-71.
64. Van Vlierberghe H, Colle I, Henrion J, et al. The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC? Acta Gastroenterol Belg 2005; 68: 403-11.
65. Yeung YP, Lo CM, Liu CL, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004.
66. Cantarini MC, Trevisani F, Morselli-Labate AM, et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 91-8.
67. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-31.
68. Giannini EG, Risso D, Testa R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 1378-84.
69. Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107: 141-8.
70. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26: 680-7.
71. Pascual S, Zapater P, Such J, et al. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006; 26: 673-9.
72. Pignata S, Gallo C, Daniele B, et al. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol 2006; 59: 243-9.
73. Tsukioka G, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma in extremely elderly patients: An analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol 2006; 12: 48-53.
74. Yeo W, Mo FK, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006; 17: 1083-9.
75. Huo TI, Huang YH, Chiang JH, et al. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: Is there a lead-time bias? Scand J Gastroenterol 2007; 42: 485-92.
76. Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007; 27: 1091-7.
77. Perry JF, Charlton B, Koorey DJ, et al. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int 2007; 27: 1240-8.
78. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13: 4345-9.
79. Tangkijvanich P, Hourpai N, Rattanatanyong P, et al. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta 2007; 379: 127-33.
80. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-7.
81. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
82. Poynard T, Aubert A, Lazizi Y, et al. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991; 13: 896-901.
83. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut 2001; 48: 251-9.
84. Melia WM, Wilkinson ML, Portmann BC, Johnson PJ, Williams R. Hepatocellular carcinoma in the non-cirrhotic liver: A comparison with that complicating cirrhosis. Q J Med 1984; 53: 391-400.
85. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. Summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver Single Topic Conference. Hepatology 2008; 47: 1764-72.
86. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.
87. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-40.
88. Huo TI, Huang YH, Lui WY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004; 11: 543-50.
89. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol 2006; 101: 524-32.